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Protodynamic Intracellular Acidification by
cis-Urocanic Acid Promotes Apoptosis of
Melanoma Cells In Vitro and In Vivo
Jarmo K. Laihia1, Janne P. Kallio2,3, Pekka Taimen4,5, Harry Kujari5, Veli-Matti Ka¨ha¨ri 2,3 and Lasse Leino1
The extracellular tumor microenvironment is acidified, whereas the intracellular pH of tumor and stromal cells
is neutral. cis-Urocanic acid (cis-UCA), an endogenous compound of the skin, can acidify the cytosol by
transporting protons into the cells. This phenomenon, termed the protodynamic concept, was studied here in
human cancer cells. cis-UCA dose-dependently reduced the number of viable human melanoma, cervical
carcinoma, and fibrosarcoma cells at weakly acidic extracellular pH. The intracellular pH decreased by up to 0.5
pH units in a concentration-dependent manner with 0.3–30mM cis-UCA at extracellular pH 6.5 but not at pH 7.4.
Under the same conditions, 30mM cis-UCA induced annexin-V binding and activation of caspase-3 in A2058
melanoma cells as signs of apoptotic cell death. Finally, growth of human melanoma xenografts in SCID mice
was suppressed by 60% following intratumoral injection of cis-UCA. Accordingly, the percentage of tumor
necrosis and active caspase-3-immunopositive cells increased, whereas proliferation activity decreased. These
results identify cis-UCA as an anticancer agent inhibiting melanoma growth by immediate intracellular
acidification followed by apoptotic cell death in vivo.
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INTRODUCTION
Urocanic acid (UCA; 3-(1H-imidazol-4-yl)prop-2-enoic acid)
is an endogenous compound in the mammalian skin. trans-
UCA, synthesized enzymatically from histidine and located
in the upper epidermis, is photo-isomerized to cis-UCA by
exposure to UV radiation. It has been well documented that
cis-UCA is able to induce immunosuppression (De Fabo and
Noonan, 1983; Norval and El-Ghorr, 2002). This may involve
cellular signaling activated through the 5-HT2A receptor
(Walterscheid et al., 2006), although this view has recently
been challenged (Woodward et al., 2006; Kaneko et al.,
2009). The endogenous concentrations of UCA in human
skin, calculated considering the mean thickness of the
epidermis, extend over the range 0.5–8.9mM (Laihia et al.,
1998). It is plausible that these concentrations have an effect
on maintaining the innate antibacterial, antiproliferative, and
anti-inflammatory environment in the epidermal layer of
human skin (‘‘acid mantle’’; Schade and Marchionini, 1928).
Accordingly, UCA has been proposed as the major acid–base
regulator in the epidermis (Krien and Kermici, 2000).
Many cellular functions in both normal and transformed cells
are regulated by intracellular pH (pHi). Intracellular acidification
modulates the proliferation of cancer cells (Thangaraju et al.,
1999; Cosentini et al., 2001; Wahl et al., 2002) and promotes
apoptosis (Gottlieb et al., 1996; Matsuyama et al., 2000). pH
below neutral may also have a positive effect on the uptake and
antiproliferative activity of some pharmacological compounds
(Jahde et al., 1989; Atema et al., 1993; Gabr et al., 1997; Wahl
et al., 2002). We have observed that cis-UCA has the ability to
penetrate into cells and acidify the cytoplasm by transporting a
proton from the weakly acidic extracellular environment to the
neutral or weakly alkaline intracellular compartment, resulting
in inhibition of the proliferation of urinary bladder cancer cells
(Laihia et al., 2009). The acid dissociation properties of cis-UCA
facilitate the transportation and release of one of the imidazolyl
protons into the cytosol (Juusola et al., 2007). We have termed
this action as the protodynamic concept (Laihia et al., 2009).
Because the proton transport is a stoichiometric reaction, that is
each cis-UCA molecule carries one proton and releases it inside
the cell, the molar concentrations of cis-UCA must be
substantially higher than when using conventional anticancer
agents. The purpose of this study was to test the protodynamic
concept in cancer cells of human origin in culture and in solid
tumor xenografts in mice with cis-UCA in a weakly acidic
aqueous vehicle. The results identify cis-UCA as an anticancer
agent capable of promoting melanoma cell apoptosis and
inhibiting tumor outgrowth by immediate intracellular acidifica-
tion and subsequent induction of programmed cell death.
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RESULTS
Inhibition of cancer cell proliferation by cis-UCA at mildly
acidic extracellular pH
cis-UCA dose dependently reduced the number of viable
human metastatic melanoma (A2058), cervical carcinoma
(HeLa), and fibrosarcoma (HT-1080) cells when tested at
extracellular pH 6.5 (Figure 1a). The IC50 concentrations
were 8.4–20mM cis-UCA in the three cell lines. To show that
the protodynamic concept is functional only in a mildly
acidic extracellular milieu typically at about pHo6.7, the
A2058 cells were first cultured for 3 days at pH 7.3 in the
absence of cis-UCA and then for 44 hours either at pH 7.4 or
pH 6.5 with or without 10mM cis-UCA. cis-UCA significantly
(P¼0.0000032) reduced the number of viable A2058 cells at
pH 6.5 (31% inhibition) but negligibly at pH 7.4 (3%
inhibition) (Figure 1b). To examine whether an extracellular
pH below neutral affects cell viability per se or sensitivity to
cis-UCA, A2058 cells were first cultured at pH 6.7 for 3 days
and then at pH 6.5 with or without 10mM cis-UCA for
44 hours. As shown in Figure 1b, the mildly acidic medium
had no effect on cell viability in the absence of cis-UCA,
whereas the response to cis-UCA was comparable to that
seen in cells pre-cultured at pH 7.3 (28% inhibition;
P¼0.0000017). Essentially similar results were obtained
with HeLa and HT-1080 cells (data not shown). Finally, the
ability of cancer cells to recover from the antiproliferative
effect of cis-UCA treatment was tested. A2058 cells were first
cultured with 10 and 30mM cis-UCA for 20 hours at pH 6.5,
followed by a recovery culture in the absence of cis-UCA for
44 hours in the same medium. After the 20-hour incubation
with cis-UCA, the number of viable cells was reduced by
39% (P¼0.021) and 74% (P¼ 0.00061) with 10 and 30mM
cis-UCA, respectively, as compared with viability in the
absence of cis-UCA. A subsequent incubation of the same
number of trypan blue-negative (viable) cells without cis-
UCA for 44 hours restored the proliferation activity of cells
pretreated with 10mM cis-UCA. However, the proliferation of
cells pretreated with 30mM cis-UCA remained significantly
suppressed (69% inhibition; P¼0.000018) (Figure 1c). The
results show that the cancer cells can recover from the
suppressed state after treatment with 10mM but not after
treatment with 30mM cis-UCA in about 2 days.
Intracellular acidification caused by cis-UCA
Flow cytometric analysis of intracellular pH (Supplementary
Methods online) in A2058 melanoma cells showed that the
pHi decreased in a dose-dependent manner with 0.3–30mM
cis-UCA in an extracellular buffer adjusted to pH 6.5,
reaching a decrease of about 0.5 pH units with 30mM cis-
UCA (Figure 1d). By contrast, the change in pHi remained in
the range of 0.1–0.18 pH units with the same cis-UCA
concentrations at the extracellular pH 7.4 and with trans-
UCA at both pH levels. The change in extracellular pH from
7.4 to 6.5 without UCA caused a decrease in pHi by 0.1 units
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Figure 1. The protodynamic anticancer effect of cis-UCA. (a) The dose response of viability (MTS assay) of three cancer cell lines after a 2-day cis-UCA
treatment at pH 6.5 (mean from duplicate incubations). (b) A2058 melanoma cells were adapted to pH 7.3 or pH 6.7 for 3 days and an equal number of viable
cells was subsequently cultured at pH 7.4 or pH 6.5 for 44 hours with or without cis-UCA (mean±SD from triplicate measurements). (c) A2058 cells were
treated with cis-UCA at pH 6.5 for 20 hours (left) and an equal number of viable cells was further cultured without cis-UCA for 44 hours (right). Cell viability was
dertermined as the number of trypan blue-negative cells. (d) The intracellular pH of A2058 cells in pH-adjusted buffer solutions containing the indicated
concentrations of cis-UCA (left) or trans-UCA (right). Inset: BCECF calibration curve.
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(Figure 1d). To our knowledge it is previously unreported that
cis-UCA is capable of acidifying the cytosol of cancer cells.
Induction of melanoma cell apoptosis by cis-UCA
Signs of early apoptosis were analyzed by annexin-V binding
to the cell membrane. Camptothecin (CPT) was used as a
positive control, which at a concentration of 0.8 mM
suppressed 88% of A2058 melanoma cell proliferation in a
2-day assay (Figure 2a). After an 18-hour treatment with
30mM cis-UCA at an acidic extracellular pH of 6.5, 33% of
the cells bound to annexin-V, compared with 7% in the
control incubation, 18% with trans-UCA, and 81% with
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Figure 2. Induction of apoptosis by cis-UCA in A2058 melanoma cells. (a) Effect of CPT on cell viability at 48 hours. (b) Annexin-V/propidium iodide
binding in cells treated with CPT, cis-UCA, or trans-UCA for 18 hours. (c) Caspase-3-like activity at pH 6.5 after 24 hours. Inset: Linearity of pNA absorption.
(d) Western blots showing caspase-3 cleavage products (single band in 10% gel) induced at 24 hours (upper panel) in a concentration-dependent manner
(lower panel). (e) Temporal induction of caspase-3-like activity (mean±SD from triplicate determinations in four independent experiments). Each time point was
assayed at least twice. The medium was not changed during these experiments. (f) The number of trypan blue-negative viable cells versus control incubation and
the (g) pH of the medium measured after each incubation.
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10 mM CPT. At pH 7.4, only 25% of the cells were annexin-V-
positive with 30mM cis-UCA and 13% with trans-UCA
treatment (Figure 2b). Incubation of the A2058 cells with
increasing concentrations of cis-UCA at pH 6.5 for 24 hours
resulted in a dramatic induction of caspase-3-like enzyme
activity (Supplementary Methods online) with 30mM cis-UCA
but not with any of the lower concentrations studied (Figure
2c). Western blotting analysis confirmed the presence of the
active caspase-3 protein in cell lysates at 24 hours but not at 3
or 6 hours of incubation with 30mM cis-UCA (Figure 2d).
Several experiments were performed to characterize the
dependence of caspase-3 activation on the duration of the
incubation. Caspase-3-like activity was induced only when
the cells were treated with 30mM cis-UCA at pH 6.5 for more
than 6 hours (Figure 2e). The cis-UCA-induced caspase-3-like
activity at pH 6.5 exceeded (Po0.001) the spontaneous
induction of activity observed at 30 and 36 hours of
continuous culture in the absence of cis-UCA (Figure 2e).
Cell viability determined as the number of trypan blue-
negative cells compared with control incubation reduced
gradually to below the 20% level at 36 hours with 30mM cis-
UCA at pH 6.5 (Figure 2f). At pH 7.4, the viability with 30mM
cis-UCA treatment approached the 50% level (Figure 2f). This
may be partially due to spontaneous acidification of the
medium after 18 hours of incubation, producing a difference
of no greater than about 0.5 pH units between the cis-UCA
treatments initially adjusted to pH 6.5 and 7.4 (Figure 2g).
Suppression of human melanoma xenograft growth by cis-UCA
in mouse in vivo
The concept of local protodynamic treatment of solid tumors
with cis-UCA was tested in an in vivo xenograft tumor model
established with human A2058 melanoma cells injected in
the skin of severe combined immunodeficient (SCID)/SCID
mice. The 1-mM concentration of CPT (Figure 2a) was chosen
for the xenograft study. At day 16 after initiating the
intratumoral treatments, the mean relative tumor area was
56% smaller (P¼0.027) in animals treated with 30mM cis-
UCA in comparison with that in the control group (Figure 3a).
The corresponding reduction in the tumor weight was 58%
(Figure 3b). The effect of cis-UCA approximately equaled that
of CPT (Figure 3a and b). The overall inhibition of tumor
growth by weight was 61% (Po0.05 at days 7–16) with cis-
UCA (Supplementary Table S1 online). No adverse local skin
or tissue reactions, or systemic complications, were observed
with any of the treatments.
In histological analysis, the untreated control tumors
showed the morphology of a typical metastasis of melanoma.
The nodule-shaped tumors showed marked nuclear atypia,
high proliferative activity, thin fibrous septa, and small
vascular structures. In addition, the tumors contained
necrotic areas and there were few inflammatory cells at the
border of the tumors. The xenograft thus serves well as a
model for invasive and metastatic human melanoma. All
tumors analyzed contained both vital and necrotic areas, the
latter being more pronounced in the cis-UCA-treated animals
(Figure 4a). The percentage of necrotic tissue was 24% in the
control tumors and 41% in the cis-UCA group (Figure 4c and
Supplementary Table S1 online). This difference was not
statistically significant (P40.05). Immunohistochemical
staining (Supplementary Methods online) showed cells
positive for active (cleaved) caspase-3 at the border of the
necrotic areas whereas the vital areas were typically negative
(Figure 4a). More active caspase-3 immunopositive cells
were detected in the tumors in the cis-UCA group where the
signs of both apoptosis and necrosis increased. The number
of proliferating (Ki-67-positive) cells was reduced from a level
of 68% in the control group to a 50% level in the cis-UCA
group (P¼ 0.023) (Figure 4b and d, and Supplementary Table
S1 online). In conclusion, the results show that cis-UCA
suppresses melanoma growth by promoting apoptotic cell
death and by inhibiting cell proliferation in vivo.
DISCUSSION
Maintenance of pHi is a prerequisite for normal cell function.
Cancer cells in a solid tumor tissue tend to form a pH gradient
across the cell membrane; the cytosolic pH is maintained at a
neutral or weakly alkaline pH, whereas the extracellular
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Figure 3. cis-UCA inhibits melanoma growth in vivo. Subcutaneous
melanoma tumors were established by injecting 2 106 A2058 cells in the
back of SCID mice and allowed to grow for 2 weeks. The tumors were then
injected with 50 ml cis-UCA (30mM), CPT (1mM), or PBS (control) three times a
week. Development of (a) tumor area and (b) tumor weight were then
followed (mean, SD). The data points have been normalized to unity in tumor
sizes at day 0 (n¼5 in each group).
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microenvironment becomes weakly acidic, usually around
pH 6.7 (Yamagata and Tannock, 1996; Kozin et al., 2001).
The acidification of the extracellular fluid in tumor tissue is a
result of both enhanced glycolytic metabolism and poor
tumor blood flow. The secreted lactate and other acidic
metabolites remain largely in the tumor tissue and make the
microenvironment weakly acidic. In this study we have tested
the protodynamic concept in which protons are carried into
cells by the cell-permeable organic acid cis-UCA. It is known
already that the proliferation of malignant cells can be
modulated by agents that alter the pHi (Thangaraju et al.,
1999; Cosentini et al., 2001; Wachsberger et al., 2002; Wahl
et al., 2002). The results of this study show that cis-UCA is
capable of causing intracellular acidification, resulting in
inhibition of cell proliferation, induction of apoptosis in
melanoma cells in vitro and in vivo, and in suppression of
tumor growth in a xenograft model in vivo. To our knowledge
this is previously unreported. We postulate that the mode of
action is based on the favorable physicochemical properties
of cis-UCA; the molecular structure possesses a biologically
‘‘active’’ proton-binding site in the imidazolyl ring
(pKa2¼6.65–7.0; Roberts et al., 1982; Zimmerman et al.,
1991; Juusola et al., 2007), which, according to basic
acid–base chemistry, remains mainly protonated at pH o7,
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Figure 4. Histological and immunohistochemical examination of A2058 melanoma tumors from SCID/SCID mice. (a) Identification of necrosis (light brown
areas, left-hand panels; bar¼ 500 mm) bordered by apoptotic cells (right-hand panels; bar¼ 50 mm). Arrowheads: Examples of cleaved caspase-3-positive
cells. (b) Ki-67 staining of tumor sections. One representative section from groups A and B is shown. Bar¼50 mm (c) A graph showing the percentage of
necrotic tumor tissue. (d) The percentages of Ki-67-positive tumor cells. The amount of positive cells was determined from areas containing the highest
proportion of immunopositive cells in the sections.
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that is in the pH milieu of the extracellular space of a solid
tumor (Figure 5). By contrast, trans-UCA, with its pKa of
5.8–6.1 (Roberts et al., 1982; Zimmerman et al., 1991;
Juusola et al., 2007), is mainly deprotonated both at pH 6.5
and pH 7.4, and thus cannot acidify the cells (Figure 1d). In
the protonated form cis-UCA is also electroneutral, which
facilitates its penetration through the plasma membrane.
When inside the cancer cell, the cytosolic pH (7.2–7.4) favors
the deprotonation of the cis-UCA molecules. Consequently,
the imidazolyl proton is released, which results in increased
acid load inside the cell (Figure 5). This process is enzyme-
and receptor-independent, and therefore not interfered by the
known mechanisms of resistance in cancer cells.
Acidification of the cytosol is able to activate an apoptotic
cellular signaling cascade (Gottlieb et al., 1996; Matsuyama
et al., 2000) within an optimal pHi range of 6.3–6.8
(Thangaraju et al., 1999; Matsuyama and Reed, 2000;
Matsuyama et al., 2000). The present results show that
treatment of the cells with cis-UCA in a weakly acidic buffer
brings the pHi into this crucial pH range (Figure 1d). In
contrast to acidification observed upon activation of the
death receptor-dependent extrinsic pathway of apoptosis, the
decrease in pH caused by the mitochondria-dependent
intrinsic pathway seems to be caspase-independent. Altera-
tions in membrane proteins or their complexes that normally
regulate the pHi have been suggested to be responsible for
acidification in response to activation of the extrinsic cascade
(Thangaraju et al., 1999; Lang et al., 2000). Intracellular
acidification may not be the initial trigger but rather a means
of enhancement, as apoptosis is also known to commence
without marked cytoplasmic acidification (Matsuyama et al.,
2000; Lagadic-Gossmann et al., 2004). Identification of these
mechanisms in the cis-UCA-dependent intracellular acidifi-
cation warrants further experimental efforts.
The results of the study indicate that both the cis-UCA
concentration and exposure time are crucial for cellular
effects. Accordingly, cis-UCA concentrations above 3mM can
produce measurable inhibition of cell proliferation (Figure 1a),
whereas the 30-mM but not the 10-mM concentration induces
caspase-3 (Figure 2c) at time points when the surviving
cells can no more recover their initial proliferation activity
(Figure 1c). This may reflect the effect of sustained intracellular
acidification, although the pHi was not measured in this study
after longer treatments with cis-UCA. The need for a sufficiently
high local concentration determines also the usage of cis-UCA
in vivo. The intratumoral injection was used as a mode of
delivery to achieve sufficiently high concentrations of cis-UCA
within the tumor tissue.
The induction of apoptosis was verified in this investiga-
tion by measuring annexin-V binding and caspase-3-like
enzyme activity in vitro and by determining the presence of
the cleaved (active) form of caspase-3 both in vitro and in
histological sections from tumors. The increased apoptosis
observed by using these end points can be regarded as an
indication that cis-UCA is able to induce a cellular process
that can neither be explained only as a consequence of a
cytotoxic effect nor as a transient cell-cycle arrest. The fact
that the A2058 melanoma cells almost fully recovered from a
treatment with 10mM cis-UCA for 20 hours (Figure 1c)
suggests that the cells can resist the pHi change caused by
this concentration for a limited time period. When the
incubation time is extended, viability clearly decreases
(Figure 1a and b). When apoptosis is induced with a higher
concentration of cis-UCA up to the point of caspase-3
activation (Figure 2b–e), the ability to proliferate is decreased
permanently (Figure 1c). In support of this observation, we
have recently shown that the effective treatment time causing
a decrease in viability can be considerably shortened in
carcinoma cell lines from the human urinary bladder by
increasing the cis-UCA concentration (Laihia et al., 2009).
We believe that this effect is not restricted only to bladder
carcinoma cells.
Both extrinsic and intrinsic pathways of apoptosis,
although differentially initiated, finally lead to activation of
effector caspases (eg, caspase-3, caspase-6, and caspase-7)
responsible for cleavage of several cellular proteins. Involve-
ment of the intrinsic pathway is suggested by a study of
human transitional bladder cancer cells (Peuhu E, Kaunisto A,
Laihia JK, Leino L, Eriksson JE, submitted). Caspase-3 is the
major effector caspase required for a typical apoptotic
phenotype (Janicke et al., 1998) and can thus be considered
the final determinant to fully launch the apoptotic machinery.
We detected active caspase-3 at the border of the necrotic
areas in both cis-UCA-treated and control tumors (Figure 4).
This may result both from the intratumoral administration
route and hypoxia-induced apoptosis. The vascularity in the
tumors was typically poor. Similarly, apoptosis occurs in the
penumbra of an ischemic lesion in the brain whereas necrotic
cell death takes place in the core of the lesion (Friedlander,
2003). The number of caspase-3-positive cells increased in
the cis-UCA-treated tumors, and there seemed to be an
association with the amount of necrosis, suggesting that
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Figure 5. The physicochemical background of the protodynamic action of cis-UCA. (From left to right) Photo-isomerization of free (extracellular) UCA normally
takes place in the acidic skin environment. At a mildly acidic pH, cis-UCA preserves one of the protons at the imidazolyl moiety. After penetration of the
electroneutral molecule into the cell cytosol with a close-to-neutral pH, the proton is released and the cytosol is acidified.
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cis-UCA induces cell death that is mediated, at least in part,
by caspase-3. The fact that the vital areas of the cis-UCA-
treated tumors were mostly negative for active caspase-3 may
be understood both by the mode of action of cis-UCA and by
the administration route. It should be noted that the treatment
phase of the study was terminated and the tumors taken
2 days after the last intratumoral injection. During the two
days, the cells in the cis-UCA-injected tumors have most
likely died and are decomposing, resulting in increased
necrotic areas and decreased apparent number of caspase-3-
positive cells. The histological sections show the degree of
caspase-3 activity at one time point only and, consequently,
the number of the end-stage apoptotic cells is difficult to
estimate at the immunohistochemical level. Furthermore, we
do not know for how long the cells stay immunopositive or
what has been their proportion in the center of the necrotic/
apoptotic areas at earlier time points.
In conclusion, this study shows a direct anticancer effect
of cis-UCA on metastatic melanoma cells in culture and in
established human melanoma xenografts in vivo. The data
indicate that cis-UCA has a potent antiproliferative and
apoptosis-inducing activity on cancer cells at the extracel-
lular pH 6.5 but limited or no activity at pH 7.4. The
modulation is related to the protodynamic action of cis-UCA
in the cell cytoplasm. The intracellular acidification cap-
ability is apparently based on the pKa2 and is thus restricted to
conditions where there is a pH difference between the intra-
and extracellular space, that is, the cytosolic pH is beyond
neutral and the extracellular environment is mildly acidic.
These pH conditions generally prevail in solid tumors.
Finally, all of the studied treatments were well tolerated by
the mice. These results provide evidence for cis-UCA as a
novel and safe regimen for pharmacological intervention in
cancer, including metastatic malignant melanoma.
MATERIALS AND METHODS
Urocanic acid
cis-UCA was synthesized by photo-isomerization of trans-UCA
(Sigma-Aldrich, St Louis, MO and Acros Organics, Geel, Belgium)
followed by anion-exchange chromatography. The purity of cis-UCA
was above 99.9% by as determined by high-performance liquid
chromatographic analysis, water content was 0.09% as found by the
Karl Fischer method, and endotoxin concentration was below
14 IUg1 as measured by the LAL gel clot method. cis-UCA was
characterized also by IR, 1H NMR, and 13C NMR spectrometry, and
by melting point analysis. cis-UCA was dissolved directly in the
incubation media. For intratumoral injections into mice, cis-UCA
was dissolved in pyrogen-free-quality phosphate-buffered saline
(PBS) and water for injection, adjusted to pH 6.5, sterile filtered,
and stored in pyrogen-free test tubes at 4–8 1C in the dark for less
than 1 week.
Cell cultures
The transformed tumorigenic cell lines A2058 (cutaneous metastatic
melanoma), HT-1080 (epithelial fibrosarcoma), and HeLa (epithelial
adenocarcinoma of the cervix) were obtained from ATCC (Manassas,
VA). The HT-1080 and HeLa cells were cultured in Iscove’s
Modified Dulbecco’s Medium and the A2058 cells were cultured
in DMEM (both from Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum and antibiotics (100 mgml1 streptomycin,
100Uml1 penicillin) under normal cell culture conditions in the
logarithmic growth phase. In vitro experiments were performed
using 15,000–75,000 viable cells in 96-well cell culture plates in a
volume of 100 or 150 ml per well.
Determination of cell viability
The proliferation rate of the cells was quantified as the number of
viable cells using a colorimetric method (CellTiter 96 AQueous One
Solution Cell Proliferation Assay; Promega, Madison, WI) that
quantifies the formation of a formazan product from the tetrazolium
compound MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) in live cells. The absor-
bance at 490 nm was read using flat-bottomed 96-well plates at
4 hours after the addition of the assay reagent.
Annexin-V binding assay
The cells treated with UCA or CPT were trypsinized and washed
with PBS and an annexin-V binding buffer consisting of 50mM
HEPES, 700mM NaCl, and 12.5mM CaCl2 (pH 7.4). To each 10
5
cells in 100 ml, 8 ml of recombinant human annexin-V–FITC
conjugate (Caltag, Burlingame, CA) and 12.5mgml1 propidium
iodide were added. After incubation at room temperature for
15minutes, 300 ml of the binding buffer was added, and the cells
were kept in an ice bath until flow cytometry analysis (FACScan;
Becton Dickinson, San Jose, CA). The data were analyzed using the
Cyflogic software (CyFlo, Turku, Finland).
Analysis of caspase-3 by western blotting
The proteins in 35 ml of the cell lysates described above,
corresponding to about 350 mg total protein, were separated by
10% SDS-PAGE and transferred to nitrocellulose membranes. To
identify active caspase-3, the blots were blocked with 5% milk in
Tris-buffered saline, incubated with a rabbit mAb against cleaved
caspase-3 (Asp 175; Cell Signaling, Danvers, MA), and a horseradish
peroxidase-conjugated polyclonal swine anti-rabbit secondary anti-
body (P0217; Dako, Glostrup, Denmark). The bands were located by
ECL detection (Amersham/GE Healthcare Life Sciences, Little
Chalfont, Buckinghamshire, UK). In another analysis, 45mg of
protein was used on a 14% gel.
Growth of human melanoma xenografts in SCID/SCID mice
All experiments with mice were performed according to institutional
guidelines and with permission of the animal test review board of the
University of Turku. The SCID/SCID mice (Charles River Labora-
tories, Wilmington, MA) were randomly allocated into treatment
groups, A, PBS (control); B, 30mM cis-UCA; and C, 1mM CPT (Sigma-
Aldrich), of six animals (three males and three females) before tumor
establishment. Human melanoma xenografts were established as
described previously (Ahonen et al., 2002; Va¨ha¨-Koskela et al.,
2006). Briefly, 2 106 cultured A2058 cells were injected sub-
cutaneously into the neck of the mice. Tumors were allowed to
develop for 2 weeks up to the size of a just measurable pearl. Each
tumor was injected intratumorally with 50 ml of test solutions three
times a week. A 27-gauge needle was used and the tumor mass was
identified by palpation. After day 7 from the beginning of the
injections, three 50-ml injections (150ml in total) were administered
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into different areas in the tumor mass three times a week. Sixteen
days after the first injection, the animals were killed with CO2. The
tumors were collected and fixed in 3.7% formaldehyde.
Tumor dimensions were measured with a caliper before
each injection by a person blinded to the treatment. The planar
area of the tumor was calculated as lengthwidth. Estimates
of tumor mass were calculated according to Equation (1) (Luciani
et al., 2004);
Tumorweight ¼ lengthðwidthÞ
2
2
ð1Þ
where the measured dimensions in mm yield an approximation of
tumor weight in mg. The tumor growth inhibition efficiency of the
treatments was calculated according to Equation (2);
Inhibition ¼ 1
Pm8
m1
SrðT Þ  1
 
Pm8
m1
SrðAÞ  1
 100% ð2Þ
where Sr represents the normalized relative tumor size (area or weight) in
the control (A) or treatment group (T), and m1–m8 are the (eight) time
points of measurement during the 16-day treatment period. One mouse
from groups A and C was killed before the end of the experiment
because of poor development of the tumor (no measurable tumor at day
0). One animal in group B was killed prematurely after it had severely
scratched the tumor. The removed animals were females. The data from
these animals were not included in the analyses.
Immunohistochemistry
The fixed tumors were embedded in paraffin. Sections of 3 mm
thickness were cut and paraffin was removed with xylene and
alcohol. The samples were boiled twice in a microwave oven in
10mM citrate buffer (pH 6.0) for 7minutes. Ki-67 staining was
performed using the Techmate immunostaining system (Bio Tek
Solutions, Santa Barbara, CA) using a rabbit anti-Ki-67 antibody
(M7420; Dako) diluted 1:100 in 1% BSA in PBS. A rabbit mAb
detecting cleaved caspase-3 (Asp 175; Cell Signaling) was diluted
1:200 in 1% BSA in PBS, and the primary immunoreaction was
localized by using a Vectastain avidin–biotin complex peroxidase
(ABC) kit (Vector, Burlingame, CA). The sections were counterstained
with hematoxylin. The amount of necrotic tumor tissue was determined
from micrographs taken with an objective magnification factor of 2.
The micrographs were divided into 540 equal areas and the percentage
of necrotic areas was counted using Corel Photo-paint 10. The
percentages of Ki-67-positive tumor cells were estimated from the
areas containing the highest proportion of immunopositive cells in each
sample. The estimation was made by two skilled persons blinded to the
group data.
Statistical analysis
Statistical significance of differences in the data from the viability
assays and tumor size measurements was calculated by two-way
Student’s t-test. Statistical significance of differences in the number
of Ki-67-positive cells and in the percentage of necrosis in the tumor
sections was evaluated by one-way analysis of variance with
Tukey–Kramer adjustment using the SAS program. The alpha level
0.05 was used in all comparisons.
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